Novel therapeutics for chronic kidney disease-mineral and bone disorder

Liangying Gan,Li Zuo

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2016.11.018

2016-01-01

Abstract:The medical management of chronic kidney disease-mineral and bone disorder (CKD-MBD) principally involves the use of the combination of phosphate binders, vitamin D or active vitamin D analogs, and/or calcimimetics.Some relatively “new” agents except calcium-containing phosphate binders and calcitriol are good clinical choices. Non-calcium containing phosphate binders including sevelamer, lanthanum carbonate, nicotinamide, sucroferricoxyhydroxide and ferric citrate are all effective in lowering phosphate levels. Also some clinical evidences show their benefits on patients' long-term survival. As active vitamin D analogs, paricalcitol, doxercalciferol and 22-oxacalcitriol can lower parathyroid hormone (PTH) levels effectively, but their other clinical benefits still need more data. Cinacalcet is currently the only available calcimimetic. It suppresses PTH by increasing the sensitivity of calcium-sensing receptor (CaSR) and complementary and potentially synergistic with vitamin D analogues. The current management of CKD-MBD principally involves early treatment and the administration of some combination of above mentioned therapeutic agents (also including calcium-containing phosphate binders and calcitriol).